Saltar para: Post [1], Pesquisa e Arquivos [2]

Noticias de Crohn - Copy.png

Assim como ontem, mais um meddicamento biossimilar aprovado, desta vez na Europa .


Resumo na língua original:

The European Commission has approved Imraldi, an adalimumab biosimilar referencing AbbVie’s Humira — making the medication available to treat the same therapeutic indications as Humira, including Crohn’s disease, pediatric Crohn’s disease and ulcerative colitis.

The Aug. 24 decision followed a positive recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use, released in June.




Imraldi will be available for any patient older than 6 years of age with moderate-to-severe active Crohn’s disease who have not responded to corticosteroid or immunosuppressant treatment regimens, or who cannot tolerate standard-of-care therapies. Imraldi will also be approved to treat adult patients moderate-to-severe ulcerative colitis who do not respond to first-line of therapy with corticosteroids and Purinethol (6-mercaptopurine) or Azasan (azathioprine), who are intolerant, or who have medical contraindications for such treatments.



Ler artigo original


Autoria e outros dados (tags, etc)

publicado às 17:43


  Pesquisar no Blog

Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.